Patients with schizophrenia appear to be at a lower risk of hospitalization for physical health issues when taking high doses of two or more antipsychotic medications concurrently (polypharmacy) than when taking just one antipsychotic medication (monotherapy) at the same dose, according to a study published yesterday in AJP in Advance.
“When patients were treated with high-dose antipsychotic monotherapy …, they had approximately a 20% higher risk of severe cardiovascular outcomes leading to hospitalization compared with periods when the same patients were treated with corresponding high-dose combination therapy,” wrote Heidi Taipale, Ph.D., of the University of Eastern Finland and colleagues.
The study included data collected from 61,889 patients diagnosed with schizophrenia who were alive on January 1, 1996, and had received inpatient care, as documented in Finland’s nationwide Hospital Discharge register. Taipale and colleagues tracked these patients up until December 31, 2017, or until they died, whichever occurred first. They specifically compared the patients’ nonpsychiatric and cardiovascular hospitalizations during periods when they were receiving antipsychotic polypharmacy versus monotherapy. The researchers also compared differences in outcomes according to antipsychotic exposure by further dividing the groups according to the following defined daily doses (DDDs): <0.4, 0.4 to <0.6, 0.6 to <0.9, 0.9 to <1.1, 1.1 to <1.4, 1.4 to <1.6, and ≥1.6. (A DDD of 1.0 reflects the average dose of a medication prescribed to an adult, according to the World Health Organization.)
Here are some of the findings they reported:
“Our results on antipsychotic use in a large nationwide cohort over a long follow-up show that antipsychotic polypharmacy is associated with lower risk of hospitalizations for physical health issues than monotherapy in the maintenance treatment of schizophrenia when high total dosage is assessed,” the authors concluded. “The current recommendations of treatment guidelines categorically encouraging use of monotherapy instead of polypharmacy are not based on evidence and should take a more agnostic approach to this issue.”
For related information, see the Psychiatric News article “Two Studies Analyze Add-On Treatments for Schizophrenia.”
(Image: iStock/Hiraman)
APA’s Psychiatry Innovation Lab nurtures early-stage ideas and ventures by investing in them with mentorship, education, and collaboration opportunities within the community of mental health innovators. Submit video pitches of ideas that aim to improve mental health care delivery and how psychiatrists diagnose, treat, and manage patients by next Friday, March 31. Four finalists will be selected to pitch their ideas to a panel of judges and audience members at APA’s 2023 Annual Meeting.